Compare BIO-TECHNE Corp (TECH) vs Unity Software Inc (U) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Unity Software Inc — how do they compare? BIO-TECHNE Corp trades at $72.03 (market cap $11.24B), while Unity Software Inc trades at $43.07 (market cap $18.97B). The key difference: Unity Software Inc is the larger of the two by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Unity Software Inc pays none. Which is the better fit depends on your goals.
| TECH | U | |
|---|---|---|
Market Cap | $11.24B | $18.97B |
Sector | Health | Technology |
52-Week High | $72.29 | $49.47 |
52-Week Low | $43.31 | $17.13 |
Enterprise Value | $11.32B | $18.85B |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Unity Software (U) trades at $43.00, up 5.37% today, with strong technical momentum and bullish analyst sentiment. The stock shows improving fundamentals with Q2 2026 earnings beating expectations, revenue growth of 24% year-over-year, and narrowing losses. Recent news highlights Vector advertising platform momentum and accelerated AI integration driving optimism.
The outlook remains positive with 69% analyst buy ratings and $47.45 consensus price target, though risks include persistent net losses, high valuation multiples, and competitive pressures. Continued execution on profitability timeline and Vector platform growth are key catalysts for further upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Unity Software Inc
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.
Read more on U →
